Compounded GLP-1 Ban: What to Do When the FDA Stops Unapproved Semaglutide and Tirzepatide

Many people moving from a compounded GLP-1 to a brand-name one wonder whether their side effects and results will change.

The window for compounded GLP-1s has closed. The FDA ended the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Now that the shortages are over, mass compounding of copies of these drugs is no longer permitted, and the FDA has continued to step up enforcement. That directly affects the many patients who relied on compounded GLP-1s as a lower-cost alternative to brand-name medications.

The end of compounding lands at a moment of maximum vulnerability: insurance coverage is contracting (CVS Caremark dropped Zepbound from its standard formulary effective July 1, 2025), and the cash-pay market for brand-name drugs is expensive. For people who have always paid cash, this is an access crisis.

Here's what's happening, who's affected, and what to do next.

What the End of Compounding Actually Means

Compounding pharmacies (both traditional "503A" pharmacies and larger "503B" outsourcing facilities) were able to make copies of tirzepatide and semaglutide because the drugs were on the FDA shortage list. The FDA's established position is that when a brand-name drug is available and not in shortage, copies should not be mass-produced.

The timeline:

The key legal distinction: compounding pharmacies were operating under the shortage exemption for tirzepatide and semaglutide. With the shortages over, that legal basis is gone. Avoid unlicensed sellers offering "compounded" versions.

Who is affected:

• Patients paying out-of-pocket for compounded tirzepatide or semaglutide
• Patients who used compounds because insurance denied coverage
• Patients who switched to compound after a savings card expired or changed terms

Who is NOT affected:

• Patients on brand-name Zepbound, Mounjaro, Wegovy, or Ozempic
• Patients with commercial insurance or Medicare coverage for brand-name GLP-1s

The Cash-Pay Crisis

People who have always paid cash have built whole coping strategies around self-pay. The end of compounding removes the primary safety valve for this group.

Brand-name prices and savings programs change often. Rather than rely on numbers that may be out of date:

Savings cards generally require commercial insurance, but manufacturer self-pay programs (LillyDirect, NovoCare) don't.

Your Alternatives When Compounded GLP-1s End

If you're currently on a compound and need to transition, here are your options.

1. Medicare (if eligible)

If you have Medicare, ask your provider whether you qualify for GLP-1 coverage. Zepbound was FDA-approved for moderate-to-severe obstructive sleep apnea with obesity in December 2024, and Medicare's GLP-1 options have been changing. Check Medicare.gov or CMS for current eligibility and costs.

Pros: Can be much cheaper than self-pay. Cons: Medicare-only, eligibility rules apply, and the rules are changing.

2. Novo Nordisk Self-Pay (NovoCare)

Novo Nordisk offers Wegovy at a self-pay price through NovoCare, without insurance. Check NovoCare for current prices.

Pros: No insurance required. Simple pricing. Cons: Semaglutide only (not tirzepatide). Still a significant monthly cost.

3. Lilly Savings Card

The Lilly savings card can reduce the cost of Zepbound for commercially insured patients, including some whose insurance doesn't cover GLP-1s. Check Lilly's site for current terms.

Pros: Works at many pharmacies. Brand-name quality. Cons: Requires commercial insurance. Card terms change periodically.

4. Self-Pay With Brand-Name

If you're uninsured, your options are limited. Some strategies:

• LillyDirect self-pay program: Eli Lilly's direct-to-patient program offers Zepbound vials at reduced pricing. Check eligibility and pricing on the LillyDirect website.
• Pharmacy discount coupons: Can reduce retail prices depending on pharmacy and location
• Comparison shop across pharmacies: Large chains, warehouse clubs, and independent pharmacies can have meaningfully different cash prices.

The Transition: What to Expect Moving From Compound to Brand

Reports from people moving from compound to brand are anecdotal, but they offer some guidance.

Efficacy Differences

Some patients report that brand-name medication feels more effective — stronger appetite suppression, more consistent results. Others report no difference. The variability may reflect differences in compounding pharmacy quality control rather than inherent differences between the molecules.

Side Effect Differences

Some people wonder whether side effects like hair shedding will change after switching. Hair shedding during GLP-1 treatment usually tracks how fast you lose weight, not whether the product was compounded or brand-name. Inconsistent potency, on the other hand, is a real concern with compounded products.

Dose Adjustment

Your prescriber will choose your brand-name starting dose, and it may not match your compounded dose. Zepbound's label starts at 2.5 mg, with maintenance doses of 5, 10 or 15 mg. Work with your provider on the transition timing and dose.

Timeline

• Start the transition process now — don't wait until your compound supply runs out
• Allow time for a provider appointment, prescription, prior authorization, and pharmacy fulfillment
• Plan for a gap — if your compound runs out before the brand-name arrives, you may have a gap. If you do, don't restart at your old dose on your own; ask your prescriber how to resume. An early mouse study from Penn Medicine (JCI Insight, March 2026) found that repeatedly stopping and restarting semaglutide led to less weight loss each cycle, though it's not yet known whether that applies to people

Resources for Navigating the Transition

The end of compounding creates a stressful transition — but it's manageable with advance planning. Key resources:

• Provider conversation: Tell your provider you need to move from compound to brand-name. They'll need to write a new prescription
• Insurance verification: Call your insurance to verify if (a) GLP-1s are covered, (b) what tier, (c) whether prior authorization is needed, (d) whether the savings card works with your plan
• Savings card enrollment: Lilly and Novo Nordisk savings programs both require enrollment — do this before you hit the pharmacy
• Medicare: If you're Medicare-eligible, ask your provider about your GLP-1 coverage options before exploring other options

If the cost means you'll be stopping instead, GLP-1 Simple's Off-Ramp Plan helps you hold your weight after the medication, with a dated 6-month plan and early regain alerts.

FAQ